Baird Capital buys Amoena for €102m

Baird Capital Partners Europe has led the buyout of Amoena, a manufacturer of breast prostheses, bras and swimwear for women who have had breast cancer surgery. The private equity firm bought the company for €102.25m ($135m) from Coloplast, a Danish medical company.

Danish medical company Coloplast has sold breast prostheses manufacturer Amoena to Baird Capital Partners Europe for €102.25 million.

Simon Havers, managing director at Baird, said: “Whilst fortunately the incidence of breast cancer is not increasing, the life-time expectancy of women following breast cancer surgery is improving and hence the increasing demand for breastcare products.”

“In addition, the detection rate for breast cancer in emerging markets has also risen in recent years and thus we expect to see an increasing demand for Amoena’s products in those territories.”

The firm’s other deals in the healthcare sector include Choices, a provider of supported living and residential care services for people with learning disabilities; Castlecare, a provider of educational and residential treatment programmes; and Ultralase, a chain of corrective eye laser clinics.

Founded in 1971, Baird Capital Partners Europe is the UK private equity business of asset manager Robert Baird and has more than €750 million under management.